Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies

Abstract Homozygous loss of the 9p21 locus encompassing CDKN2A, CDKN2B, and MTAP is the most frequent copy number alteration across tumor types, making it a promising target for precision medicine strategies. To explore drug vulnerabilities exposed by this loss, we generated 9p21 locus isogenic blad...

Descripció completa

Dades bibliogràfiques

Autors principals:	Riccardo Bevilacqua, Paola Gasperini, Thomas Cantore, Catarina Macedo-Silva, Michael Pancher, Martina Radić, Haiyan Yue, Orsetta Quaini, Tarcisio Fedrizzi, Pamela Gatto, Roland Seiler, Bernhard Kiss, Valentina Adami, Francesca Lorenzin, Marianna Kruithof-de Julio, Bishoy Morris Faltas, Francesca Demichelis
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-04-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-026-01434-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!